Speirs R L
Hunterian Institute, Royal College of Surgeons, London.
Dent Update. 1991 May;18(4):166-71.
Normal haemostasis depends on a balance between coagulation and fibrinolytic processes. Because of this concept of balance between coagulation and fibrinolysis, drugs which retard or inhibit the breakdown of fibrin encourage haemostasis. Such drugs are used in patients undergoing dental extractions and as prophylactic agents to prevent spontaneous bleeding. Blood clotting factors produced by genetic engineering are now becoming available and these offer exciting prospects for the management of patients with bleeding disorders.
正常止血依赖于凝血和纤溶过程之间的平衡。基于凝血与纤溶平衡的这一概念,延缓或抑制纤维蛋白分解的药物可促进止血。此类药物用于拔牙患者以及作为预防自发性出血的预防剂。通过基因工程生产的血液凝血因子现已问世,这些为出血性疾病患者的治疗提供了令人兴奋的前景。